Skip to main content
letter
. 2018 Mar;103(3):e119–e122. doi: 10.3324/haematol.2017.179044

Figure 1.

Figure 1.

In vivo effect of ibrutinib in CLL patients over a follow-up period of 12 months. (A) Platelet agglutination by 1.2 mg/ml ristocetin. (B) platelet aggregation by 3.3 μg/ml collagen. (C) plasma von Willebrand factor antigen. Horizontal lines indicate median values.